CSL Limited trades at a decade-low P/E, despite ongoing revenue and profit growth, presenting significant upside potential. Learn more about CMXHF stock here.

What do market analysts think of these mega healthcare companies? The post 3 ASX 200 large-cap healthcare shares just ...

The CSL Ltd (ASX: CSL) share price hit a 52-week low of $253.95 on Wednesday. Since the end of July 2024, it has dropped close to 20%. Investors may be asking themselves whether this ASX blue-chip ...

After a sharp sell-off, expectations have reset. The key question is whether the business has truly changed. The post Are CSL ...

CSL says plasma donors can earn up to $100 per donation and as much as $750 per month. Here’s how it works and what to watch ...

Chronic Lyme disease isn't recognized by conventional medicine. It's a controversial term used by some alternative practitioners to describe pain, fatigue and neurological symptoms they attribute to a ...

The European Commission has approved Otsuka's Dawnzera for the prevention of recurrent attacks in rare disease hereditary angioedema (HAE), a drug that can be self-administered by patients with weeks ...

Let's see if analysts are bullish, bearish, or something in-between with these shares. The post Buy, hold, sell: BHP, CSL, ...

UiPath Chief Marketing Officer Michael Atalla argues that enterprises aren’t moving toward agent-only automation, but toward a permanent hybrid model that combines deterministic workflows, AI agents, ...

British Columbia Investment Management Corporation has named Jon Salon executive vice-president and global head, private ...

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring ...